Trial site
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi 541100, ChinaNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 36 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting10 trials
- Recruiting5 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.5 trials
- RemeGen Co., Ltd.3 trials
- Pfizer2 trials
- Abbisko Therapeutics Co, Ltd1 trial
- Amgen1 trial
- and 5 more
Running trials
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Recruiting
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865· Phase 2· RemeGen Co., Ltd.· Source
Contact: Heping Liu
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Bihui Li
Recruiting
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
NCT07141056· Guilin Medical University, China· Source
Contact: Xueyao Wang, MM
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Active, not recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679· Amgen· Source
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769· Phase 2/3· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
NCT05020457· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499· Phase 1/2· Klus Pharma Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error